Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest announcement is out from Wai Yuen Tong Medicine Holdings Limited ( (HK:0897) ).
Wai Yuen Tong Medicine Holdings Limited announced its final results for the year ended 31 March 2025, reporting a decrease in revenue by 4.9% to HK$745.3 million from continuing operations. Despite the revenue decline, the company saw a significant improvement in profitability, with profit for the year increasing by 77.5% to HK$7.1 million, and earnings per share rising by 148.5%. The company’s net assets value and cash equivalents saw a decline, but the gearing ratio improved slightly. These results indicate a positive shift in the company’s financial performance, potentially enhancing its market position and offering a more favorable outlook for stakeholders.
More about Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited is a company incorporated in Bermuda with limited liability, primarily engaged in the pharmaceutical industry. It focuses on the production and sale of traditional Chinese medicine and health products.
Average Trading Volume: 473,710
Technical Sentiment Signal: Buy
Current Market Cap: HK$376.9M
For detailed information about 0897 stock, go to TipRanks’ Stock Analysis page.